Brief: Biosion Licenses BSI-060T (Anti-Siglec-15) To Pyxis Oncology
29/03/2022 18:48
March 29 (Reuters) - Biosion:
* BIOSION LICENSES BSI-060T (ANTI-SIGLEC-15) TO PYXIS
ONCOLOGY
* BIOSION - PYXIS ONCOLOGY WILL BE RESPONSIBLE FOR
DEVELOPMENT AND
COMMERCIALIZATION OF BSI-060T (NOW REFERRED TO AS PYX-106)
* BIOSION - EARNS A $10 MILLION UPFRONT LICENSE FEE;
ADDITIONAL
MILESTONE PAYMENTS & ROYALTIES ON COMMERCIAL SALES TO BE EARNED
UPON ADVANCEMENT OF PYX-106
* BIOSION - HAS POTENTIAL TO RECEIVE MILESTONE PAYMENTS FOR
PYX-106, TOTALING UP TO $222.5 MILLION & SINGLE TO LOW
DOUBLE-DIGIT ROYALTIES ON COMMERCIAL SALES
* BIOSION - PYXIS ONCOLOGY PLANS ON SUBMITTING IND FOR
PYX-106 TO
FDA BY H2 OF 2022 AND INITIATING A PHASE 1 TRIAL SHORTLY
THEREAFTER
* BIOSION - PYXIS ONCOLOGY HAS OPPORTUNITY TO LICENSE
ADDITIONAL
PRECLINICAL ASSETS THAT TARGET ANTI-SIGLEC-15 USING OTHER
APPROACHES TO TREATMENT
Source text for Eikon: urn:newsml:reuters.com:*:nPn6QkjgXa
Further company coverage: PYXS.O
((Reuters.Briefs@thomsonreuters.com;))